Drug Therapy
Mostrando 1-12 de 1998 artigos, teses e dissertações.
-
1. Quais são as indicações de encaminhamento para cirurgia bariátrica?
O tratamento cirúrgico da obesidade (cirurgia bariátrica) pode ser indicado nos pacientes com IMC ≥ 40kg/m² ou em pacientes com IMC ≥ 35 associado a comorbidades como: risco cardiovascular maior que 20% em dez anos, doença cardiovascular, hipertensão arterial de difícil controle, diabetes mellitus de difícil controle, síndrome da apneia e hipo
Núcleo de Telessaúde Rio Grande do Sul. Publicado em: 12/06/2023
-
2. Deve-se retirar a sulfonilureia quando for iniciada a insulina em pacientes com diabetes tipo 2 usando metformina e sulfonilureia em doses máximas e sem controle glicêmico adequado?
Não é necessário retirar a sulfonilureia ao iniciar insulina NPH em pacientes com diabetes tipo 2. A manutenção do uso da sulfonilureia durante o início do tratamento com insulina NPH (insulina basal) está associada ao uso de doses 30% menores de insulina, menor risco de hipoglicemias e menor ganho de peso.
Deve-se suspender a sulfonilureia e
Núcleo de Telessaúde Rio Grande do Sul. Publicado em: 12/06/2023
-
3. Como deve ser feita a inibição da lactação?
Métodos não farmacológicos:
– Evitar a sucção e outras formas de estímulo.
– Aplicar compressas frias durante 10 minutos, 4 vezes ao dia.
– Fazer enfaixamento compressivo, com ataduras elásticas por volta de 7 a 10 dias após o parto, com cuidado para não restringir os movimentos respiratórios ou causar desconforto materno
Núcleo de Telessaúde Rio Grande do Sul. Publicado em: 12/06/2023
-
4. Long-term consequences of osteoporosis therapy with denosumab
ABSTRACT Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension for up to 10 years. Those who were randomized to DMAb conti
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
5. Anabolic therapy for osteoporosis: update on efficacy and safety
ABSTRACT Anabolic agents for the treatment of osteoporosis increase bone density, improve bone strength, and reduce fracture risk. They are distinguished from antiresorptive drugs by their property of increasing osteoblastic bone formation. Teriparatide and abaloparatide are parathyroid hormone receptor agonists that increase bone remodeling with bone format
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
6. Use of prescribed psychotropic drugs among medical students and associated factors: a cross-sectional study
Abstract BACKGROUND: The worldwide prevalences of anxiety and depressive disorders are 3.6% and 4.4%, respectively. Among medical students, many studies have indicated that the prevalences of these mental disorders vary between 19.7% and 47.1%, but there is a lack of information on psychotropic drug usage in this group of students. OBJECTIVE: To evaluate t
Sao Paulo Medical Journal. Publicado em: 2022
-
7. Surgical Management of The Endomyocardial Fibrosis of Right Ventricle Mimicking Tumor with Recurrent Pulmonary Embolism
ABSTRACT Endomyocardial fibrosis is a neglected tropical disease that leads to restrictive cardiomyopathy. Its etiopathogenis is unclear and involves the progression of 3 stages of the disease. Compared with echocardiography, cardiac magnetic resonance imaging shows better apical visualization of obliteration and thrombus and provides an early diagnosis. How
Brazilian Journal of Cardiovascular Surgery. Publicado em: 2022
-
8. Pharmaceutical Care in Primary Care: an Experience with Hypertensive Patients in the North of Brazil
Abstract Background: Uncontrolled blood pressure has been associated with poor adherence to drug treatment. Objectives: To assess blood pressure control in hypertensive patients attending primary health centers after implementation of a pharmaceutical follow-up program in a city of the north of Brazil. Methods: Observational, cross sectional, descriptive
International Journal of Cardiovascular Sciences. Publicado em: 2022
-
9. Clinical diagnosis and treatment of primary thyroid tuberculosis: a retrospective study
ABSTRACT BACKGROUND: Primary thyroid tuberculosis (PTT) is an uncommon type of extrapulmonary tuberculosis, which is caused by Mycobacterium tuberculosis. It does not have specific clinical manifestations, and most cases are diagnosed through postoperative histopathological examination. OBJECTIVE: To evaluate the diagnostic pattern and management strategy
Sao Paulo Medical Journal. Publicado em: 2022
-
10. Comparison of efficacy of three commonly used alpha-blockers as medical expulsive therapy for distal ureter stones: A systematic review and network meta-analysis
ABSTRACT Introduction: The efficacy of alpha-blockers as medical expulsive therapy (MET) is well established. However, it is not known which of the three most commonly used alpha-blockers (tamsulosin, alfuzosin and silodosin) is the most efficacious. With this study we aimed to assess the efficacy of the three commonly used alpha-blockers as MET for distal
International braz j urol. Publicado em: 2022
-
11. Factors affecting recurrence in subacute granulomatous thyroiditis
ABSTRACT Objective: This study aimed to evaluate the factors affecting recurrence in subacute granulomatous thyroiditis (SAT). Materials and methods: A total of 137 patients with SAT were enrolled in the study; 98 (71.5%) were women and 39 (28.5%) were men. The patients received either steroid or nonsteroidal anti-inflammatory drug (NSAID) for eight weeks.
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
12. Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study
Abstract Background: Clinical studies have demonstrated that IL-17A inhibition with secukinumab is effective for clearing the skin of patients with psoriasis and has a favorable safety profile. Objective: The authors aim to determine whether secukinumab is effective and safe for the treatment of moderate-to-severe chronic psoriasis based on clinical experi
Anais Brasileiros de Dermatologia. Publicado em: 2022